IceCure Medical Ltd. (ICCM) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, and thank you for standing by. Currently, all of the participants are in listen-only mode. After management discussion, there will be a question-and-answer session. Please be advised that today's conference call is being recorded. I would now like to turn the conference over to Michael Polivier. Please go ahead. Thank you, Ella, and welcome to Ice Care Medical's conference call to review financial results as of and until the nine months ended, September 30, 2025, and provide an update on recent operational highlights. You may refer to the earnings press release that we issued earlier this morning. Participating on today's call are Ice Care Medical's CEO, Al Shamir, and the company's CFO, Ronan Zerman. Before we begin, I will now take a moment to read a statement about both the statements. This call and the question and answer session that follows it contains forward look statements within the meaning of the safe harbor provisions of the private securities litigation reform act of 1995 and other federal securities law. Words such as expects, anticipates, intends, plans, believes, seeks, estimates and similar expressions or variations of such words are intended to identify forward look statements. For example, we are using forward look statements in this presentation when we discuss that the FDA's marketing authorization for ProSense will drive meaningful growth for us and support broader action for patients. The belief that global interest following the FDA authorization will support international adoption, the belief that ProSense will be the only cryoablation system cleared in the U.S. for breast cancer in the foreseeable future, the expectation that Terumo Corporation will submit a regulatory application for ProSense in Japan in the first half of 26, ...